Overview
Wojtek Mydlarz, director of Johns Hopkins Head and Neck Surgery in the National Capital Region, specializes in the treatment of benign and malignant tumors of the head and neck, including the upper aerodigestive tract, salivary glands, skull base, thyroid, skin and soft tissue. Dr. Mydlarz is a medical officer and a clinical and research collaborator in the head and neck surgery branch of the National Institutes of Health (NIH). His research interests include evaluating both surgical and nonsurgical treatment outcomes in patients with head and neck cancer. He is interested in the complex molecular biology of head and neck cancer, as well as potential clinical applications of novel targeted cancer therapies. He is actively involved in clinical trial development and implementation at the NIH and Johns Hopkins. After earning his medical degree from the Johns Hopkins University School of Medicine, Dr. Mydlarz completed his internship and residency in otolaryngology–head and neck surgery at The Johns Hopkins Hospital. Additionally, he completed a Science of Clinical Investigation Training Program at Johns Hopkins Bloomberg School of Public Health and specialized fellowship training in head and neck surgical oncology at the University of Texas MD Anderson Cancer Center. Dr. Mydlarz has contributed to numerous professional publications, authored a variety of articles and book chapters, and has been invited to give many lectures. He serves on the editorial board for Oral Oncology and Laryngoscope Investigative Otolaryngology, and is a journal reviewer for Oral Oncology, Head and Neck, Laryngoscope and JAMA Otolaryngology–Head and Neck Surgery.
Dr. Mydlarz is rated as an Experienced provider by MediFind in the treatment of Polymorphous Low Grade Adenocarcinoma. His top areas of expertise are Head and Neck Squamous Cell Carcinoma (HNSCC), Tongue Cancer, Salivary Gland Tumors, Laryngectomy, and Glossectomy.
His clinical research consists of co-authoring 41 peer reviewed articles. MediFind looks at clinical research from the past 15 years.
Insurance
Accepted insurance can change. Please verify directly with the provider.
Accepted insurance plans:
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- POS
- PPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE-MEDICAID PLAN
- OTHER COMMERCIAL
- OTHER MEDICARE
- OTHER MEDICARE PART D
- PPO
- HMO
- POS
- PPO
- EPO
- HMO
- PPO
- INSURANCE PLAN
- MEDICARE PDP
- PPO
- HMO
- POS
- PPO
- HMO
- INDEMNITY
- POS
- PPO
- HMO
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE-MEDICAID PLAN
- OTHER MANAGED MEDICAID
- OTHER MEDICAID
- STATE MEDICAID
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE PART D
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE
- OTHER MEDICARE PART D
Locations
6420 Rockledge Drive, Suite 4920, Suite 4920, Bethesda, MD 20817
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Johns Hopkins Outpatient Center
Head and neck surgeon David Eisele specializes in surgery for malignant and benign tumors of the head and neck, with a focus on salivary gland neoplasms and disorders of the salivary glands that can be treated surgically. He is an expert in minimally invasive surgical approaches, including sialendoscopy. Salivary gland neoplasms and disorders are also the focus of Dr. Eisele’s research. He has published more than 300 research papers and edited multiple books related to head and neck surgery. Dr. Eisele earned a medical degree from Cornell University Medical College and completed residency training in general surgery and in otolaryngology–head and neck surgery at the University of Washington. From 2012 to 2025, he served as director of the Department of Otolaryngology–Head and Neck Surgery at the Johns Hopkins University School of Medicine. Dr. Eisele is rated as an Elite provider by MediFind in the treatment of Polymorphous Low Grade Adenocarcinoma. His top areas of expertise are Salivary Duct Stones, Salivary Gland Tumors, Throat Cancer, Laryngectomy, and Gastrostomy.
David Sidransky is an Oncologist and an Otolaryngologist in Baltimore, Maryland. Dr. Sidransky is rated as a Distinguished provider by MediFind in the treatment of Polymorphous Low Grade Adenocarcinoma. His top areas of expertise are Head and Neck Squamous Cell Carcinoma (HNSCC), Adenoid Cystic Carcinoma, Salivary Gland Tumors, and Polymorphous Low Grade Adenocarcinoma.
Johns Hopkins University
Dr. Tanguy Seiwert is an oncologist in Baltimore, caring for patients with head and neck cancer. He serves as the director of the Head and Neck Cancer Oncology Disease Program and the co-director of the Bloomberg~Kimmel Institute for Immunotherapy at the Head and Neck Cancer Program at the Johns Hopkins School of Medicine. Dr. Seiwert earned his M.D. at Johannes Gutenberg Universität in Mainz, Germany. He completed his residency at the Duke University School of Medicine and performed a fellowship in hematology/oncology at the University of Chicago Medicine Mitchell Hospital-Hyde Park. Dr. Seiwert joined the Johns Hopkins faculty in 2019. Prior to joining Johns Hopkins, Dr. Seiwert was director of the Head and Neck Cancer Program at the University of Chicago. Dr. Seiwert’s research interests include immunologic and genomic profiling. He has given numerous invited talks on head and neck cancer both nationally and internationally. Dr. Seiwert served as chief editor for Frontiers in Head and Neck Cancer and as an editorial board member for the Journal of Clinical Oncology and Oral Oncology. He is a reviewer for multiple medical journals, including Lancet Oncology, Annals of Oncology and Clinical Cancer Research. He has been recognized by the American Association for Clinical Oncology for multiple Merit Awards and a Young Investigator Award. He was a member of the NCI Head and Neck Cancer Steering Committee, and is a member of the American Association for Clinical Oncology, the Society for Immunotherapy of Cancer, and the European Society of Clinical Oncology. Dr. Seiwert is rated as an Advanced provider by MediFind in the treatment of Polymorphous Low Grade Adenocarcinoma. His top areas of expertise are Glioma, Laryngeal Cancer, Tongue Cancer, Oral Squamous Cell Carcinoma, and Gastrostomy.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Distinguished
- Head and Neck Squamous Cell Carcinoma (HNSCC)Dr. Mydlarz isDistinguished. Learn about Head and Neck Squamous Cell Carcinoma (HNSCC).
- Advanced
- Oral Squamous Cell CarcinomaDr. Mydlarz isAdvanced. Learn about Oral Squamous Cell Carcinoma.
- Salivary Gland TumorsDr. Mydlarz isAdvanced. Learn about Salivary Gland Tumors.
- Tongue CancerDr. Mydlarz isAdvanced. Learn about Tongue Cancer.
- Experienced
- Acinic Cell Carcinoma of Salivary GlandsDr. Mydlarz isExperienced. Learn about Acinic Cell Carcinoma of Salivary Glands.
- Adenoid Cystic CarcinomaDr. Mydlarz isExperienced. Learn about Adenoid Cystic Carcinoma.
- Angiosarcoma of the ScalpDr. Mydlarz isExperienced. Learn about Angiosarcoma of the Scalp.
- Aseptic and Alopecic Nodules of Scalp (AANS)
- Deafness Craniofacial SyndromeDr. Mydlarz isExperienced. Learn about Deafness Craniofacial Syndrome.
- Familial Isolated HyperparathyroidismDr. Mydlarz isExperienced. Learn about Familial Isolated Hyperparathyroidism.